Panitumumab Beats Bevacizumab in Left-Sided mCRC Panitumumab Beats Bevacizumab in Left-Sided mCRC

The first trial comparing panitumumab or bevacizumab plus standard chemotherapy has shown that the former significantly improves survival in left-sided Ras wild type metastatic colorectal cancer.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news